Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease
The study meets the primary safety endpoint; positive secondary efficacy assessments support potential benefit from Lomecel-B Decline in cognitive function slower in patients who received low-dose Lomecel-B as compared with placebo Quality of life metrics improved with Lomecel-B compared to placebo Complete results being prepared for publication. On track to initiate Phase 2 study in …